Novel Biomarkers for Coronary Restenosis Occurrence After
Drug-Eluting Stent Implantation in Patients With Diabetes
Having Stable Coronary Artery Disease

J 2018

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease

GABBASOV, Zufar; Sergey KOZLOV; Ivan MELNIKOV; Svetlana BYAZROVA; Olga SABUROVA et al.

Základní údaje

Originální název

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease

Autoři

GABBASOV, Zufar; Sergey KOZLOV; Ivan MELNIKOV; Svetlana BYAZROVA; Olga SABUROVA; Lyudmila PROKOFIEVA; Martin CAPRNDA; Eduard CURILLA; Ludovit GASPAR; Luis RODRIGO; Peter KRUŽLIAK a Vladimir SMIRNOV

Vydání

Clinical and Applied Thrombosis-Hemostasis, Thousand Oaks, Sage Publications Inc. 2018, 1076-0296

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.846

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/18:00104227

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

coronary artery disease; diabetes mellitus; drug-eluting stents; restenosis; CD45+platelet count; neutrophil to lymphocyte ratio

Štítky

14110121, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 2. 2019 16:56, Soňa Böhmová

Anotace

V originále

The purpose of the study was to assess whether the occurrence of restenosis is associated with CD45+ platelet count and neutrophil to lymphocyte ratio in patients with type 2 diabetes mellitus (DM) after drug-eluting stent (DES) implantation for stable coronary artery disease (CAD). The study comprised 126 patients, including 55 patients with type 2 DM and stable CAD who underwent elective coronary artery stenting with DES and follow-up angiography within 6 to 12 months. Blood samples were collected from each patient on the morning of the coronary angiography procedure. The variables related to in-stent restenosis were selected by logistic regression analysis. The logistic regression analysis showed that 2 inflammatory factors, CD45+ platelet count (odds ratio [OR] = 4.51, 95% confidence interval [CI]: 1.50-13.50, P = .007) and neutrophil to lymphocyte ratio (OR = 3.09, 95% CI: 1.05-9.10, P = .04), were significantly associated with the risk of in-stent restenosis after stenting with DES in patients with stable CAD and type 2 DM. A receiver operator characteristic curve analysis indicated that the area under the curve was 0.83% (0.05%; P < .001), which showed that the logistic model had good predictive accuracy (based on CD45+ platelet count and neutrophil to lymphocyte ratio) for the risk of in-stent restenosis development in DES in patients with CAD and type 2 DM. Two novel biomarkers of restenosis, CD45+ platelet count and neutrophil to lymphocyte ratio, may be effectively used to predict in-stent restenosis after DES implantation in patients with CAD and type 2 DM.

Citovat

GABBASOV, Zufar; Sergey KOZLOV; Ivan MELNIKOV; Svetlana BYAZROVA; Olga SABUROVA; Lyudmila PROKOFIEVA; Martin CAPRNDA; Eduard CURILLA; Ludovit GASPAR; Luis RODRIGO; Peter KRUŽLIAK a Vladimir SMIRNOV. Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease. Clinical and Applied Thrombosis-Hemostasis. Thousand Oaks: Sage Publications Inc., 2018, roč. 24, č. 8, s. 1308-1314. ISSN 1076-0296. Dostupné z: https://doi.org/10.1177/1076029618771752.

@article{1456256,
   author = {Gabbasov, Zufar and Kozlov, Sergey and Melnikov, Ivan and Byazrova, Svetlana and Saburova, Olga and Prokofieva, Lyudmila and Caprnda, Martin and Curilla, Eduard and Gaspar, Ludovit and Rodrigo, Luis and Kružliak, Peter and Smirnov, Vladimir},
   article_location = {Thousand Oaks},
   article_number = {8},
   doi = {https://doi.org/10.1177/1076029618771752},
   keywords = {coronary artery disease; diabetes mellitus; drug-eluting stents; restenosis; CD45+platelet count; neutrophil to lymphocyte ratio},
   language = {eng},
   issn = {1076-0296},
   journal = {Clinical and Applied Thrombosis-Hemostasis},
   title = {Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease},
   volume = {24},
   year = {2018}
}

TY  - JOUR
ID  - 1456256
AU  - Gabbasov, Zufar - Kozlov, Sergey - Melnikov, Ivan - Byazrova, Svetlana - Saburova, Olga - Prokofieva, Lyudmila - Caprnda, Martin - Curilla, Eduard - Gaspar, Ludovit - Rodrigo, Luis - Kružliak, Peter - Smirnov, Vladimir
PY  - 2018
TI  - Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease
JF  - Clinical and Applied Thrombosis-Hemostasis
VL  - 24
IS  - 8
SP  - 1308-1314
EP  - 1308-1314
PB  - Sage Publications Inc.
SN  - 10760296
KW  - coronary artery disease
KW  - diabetes mellitus
KW  - drug-eluting stents
KW  - restenosis
KW  - CD45+platelet count
KW  - neutrophil to lymphocyte ratio
N2  - The purpose of the study was to assess whether the occurrence of restenosis is associated with CD45+ platelet count and neutrophil to lymphocyte ratio in patients with type 2 diabetes mellitus (DM) after drug-eluting stent (DES) implantation for stable coronary artery disease (CAD). The study comprised 126 patients, including 55 patients with type 2 DM and stable CAD who underwent elective coronary artery stenting with DES and follow-up angiography within 6 to 12 months. Blood samples were collected from each patient on the morning of the coronary angiography procedure. The variables related to in-stent restenosis were selected by logistic regression analysis. The logistic regression analysis showed that 2 inflammatory factors, CD45+ platelet count (odds ratio [OR] = 4.51, 95% confidence interval [CI]: 1.50-13.50, P = .007) and neutrophil to lymphocyte ratio (OR = 3.09, 95% CI: 1.05-9.10, P = .04), were significantly associated with the risk of in-stent restenosis after stenting with DES in patients with stable CAD and type 2 DM. A receiver operator characteristic curve analysis indicated that the area under the curve was 0.83% (0.05%; P < .001), which showed that the logistic model had good predictive accuracy (based on CD45+ platelet count and neutrophil to lymphocyte ratio) for the risk of in-stent restenosis development in DES in patients with CAD and type 2 DM. Two novel biomarkers of restenosis, CD45+ platelet count and neutrophil to lymphocyte ratio, may be effectively used to predict in-stent restenosis after DES implantation in patients with CAD and type 2 DM.
ER  -

GABBASOV, Zufar; Sergey KOZLOV; Ivan MELNIKOV; Svetlana BYAZROVA; Olga SABUROVA; Lyudmila PROKOFIEVA; Martin CAPRNDA; Eduard CURILLA; Ludovit GASPAR; Luis RODRIGO; Peter KRUŽLIAK a Vladimir SMIRNOV. Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease. \textit{Clinical and Applied Thrombosis-Hemostasis}. Thousand Oaks: Sage Publications Inc., 2018, roč.~24, č.~8, s.~1308-1314. ISSN~1076-0296. Dostupné z: https://doi.org/10.1177/1076029618771752.

Přehled o publikaci